sygnaturediscovery.com

Avaliação do site sygnaturediscovery.com

Sygnature Discovery - Leading Contract Research Organisation

 Gerado a 06 de Abril de 2026 22:57 PM

Estatísticas desatualizadas? ATUALIZE !

O resultado é de 63/100

Conteúdo SEO

Título

Sygnature Discovery - Leading Contract Research Organisation

Cumprimento : 60

Perfeito, o Título contém entre 10 e 70 caracteres.

Descrição

Sygnature Discovery is a world-leading integrated drug discovery CRO based in the UK and Canada with headquarters in Nottingham (UK).

Cumprimento : 133

Perfeito, a Descrição META contém entre 70 e 160 caracteres.

Palavras-chave

Mau. Não detetámos palavras-chave META na sua página.

Propriedades Og Meta

Boa! Esta página tira vantagens das propriedades Og.

Propriedade Conteúdo
locale en_US
type website
title Sygnature Discovery - Leading Contract Research Organisation
description Sygnature Discovery is a world-leading integrated drug discovery CRO based in the UK and Canada with headquarters in Nottingham (UK).
url https://www.sygnaturediscovery.com/
site_name Sygnature
image https://www.sygnaturediscovery.com/wp-content/uploads/2026/02/sygnature-hit-to-lead-team-collaboration-scaled.webp
image:width 2560
image:height 1707
image:type image/webp

Cabeçalhos

H1 H2 H3 H4 H5 H6
1 25 28 137 8 0
  • [H1] Achieving exceptional scientific outcomesthrough connected drug discovery.
  • [H2] World-leading drug discovery solutions, accelerating your compound to the clinic.
  • [H2] We offer deep expertise across the full range of drug discovery solutions.
  • [H2] We deliver world-class scientific expertise and flexible services across every discipline in preclinical discovery.
  • [H2] Integrated Drug Discovery
  • [H2] Computer Aided Drug Design
  • [H2] Protein & Structure
  • [H2] Bioscience
  • [H2] Chemistry
  • [H2] Drug Metabolism and Pharmacokinetics (DMPK)
  • [H2] in vivo Pharmacology
  • [H2] Form and Formulation
  • [H2] We offer specialist expertise across a range of modalities, target classes and therapeutic areas.
  • [H2] Modalities
  • [H2] Target Classes
  • [H2] Therapeutic Areas
  • [H2] World-leading drug discovery
  • [H2] At Sygnature Discovery, we create exceptional scientific outcomes
  • [H2] Reshaping drug discovery by uniting technology, disciplines and talent across Europe and North America
  • [H2] Impact that lasts
  • [H2] Our track record
  • [H2] Trusted by customers worldwide
  • [H2] Interested in joining our team?
  • [H2] News & Resources
  • [H2] Ready to start a conversation?
  • [H2] You're in the right place!
  • [H3] Featured Resources
  • [H3] Featured Resources
  • [H3] Featured Resources
  • [H3] in vivo Pharmacology solutions
  • [H3] Featured Resources
  • [H3] Ion channels Ion channels
  • [H3] Featured Resources
  • [H3] Featured Resources Overview
  • [H3] Featured Resources
  • [H3] Categories View all
  • [H3] Featured Resources
  • [H3] Featured Resources
  • [H3] Featured Resources
  • [H3] Featured Resources
  • [H3] in vivo Pharmacology solutions
  • [H3] Featured Resources
  • [H3] Ion channels Ion channels
  • [H3] Featured Resources
  • [H3] Featured Resources
  • [H3] Categories View all
  • [H3] Featured Resources
  • [H3] From Lead to Pre-Candidate Nomination in 18 Months
  • [H3] Sitryx: Empowering New Ideas
  • [H3] Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
  • [H3] Corcept Therapeutics: Integrated Drug Discovery Collaboration
  • [H3] CellCentric Lead Optimisation Campaign – CCS1477
  • [H3] Fragment-based hit discovery for the epigenetic target, BRD3
  • [H3] Hit Identification to 3 Compounds in the Clinic and 6 Development Candidates
  • [H4] Integrated Drug Discovery
  • [H4] Target Identification & Validation
  • [H4] Hit Identification
  • [H4] Hit-to-Lead
  • [H4] Lead Optimization
  • [H4] STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
  • [H4] Computer Aided Drug Design
  • [H4] Bioinformatics
  • [H4] Target Analysis
  • [H4] Virtual Screening
  • [H4] Structure Based Drug Design
  • [H4] Generative AI and Machine Learning
  • [H4] Ligand Based Drug Design
  • [H4] Library Design
  • [H4] ADMET Predictions
  • [H4] Informatics
  • [H4] Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
  • [H4] Protein Science and Structural Biology
  • [H4] Protein Expression and Purification
  • [H4] Membrane Proteins
  • [H4] Antibodies and Biotherapeutics
  • [H4] Structural Biology
  • [H4] X-Ray Crystallography
  • [H4] cryo-EM
  • [H4] Macromolecular NMR
  • [H4] Protein Characterization
  • [H4] Protein Mass Spectrometry
  • [H4] FIDA
  • [H4] A Comparison of the Structural Techniques used at Sygnature Discovery: X-ray Crystallography, NMR and Cryo-EM
  • [H4] Bioscience
  • [H4] Cell Line Generation
  • [H4] Assay Development
  • [H4] Electrophysiology
  • [H4] High Throughput Screening
  • [H4] Cell Based Assays
  • [H4] Biochemical Assays
  • [H4] Biophysical Assays
  • [H4] Primary Cells and Tissues
  • [H4] Integrating Hit Finding and Direct-to-Biology to Shorten Time to Development Candidate
  • [H4] Chemistry
  • [H4] Medicinal Chemistry
  • [H4] Synthetic Chemistry
  • [H4] Process & Scale-up Chemistry
  • [H4] NMR-Spectroscopy
  • [H4] Separation Sciences
  • [H4] High Throughput Chemistry
  • [H4] Why Early Process Chemistry Matters?
  • [H4] Drug Metabolism and Pharmacokinetics
  • [H4] Physicochemical Profiling
  • [H4] Chemical & Metabolic Stability
  • [H4] Permeability
  • [H4] Tissue Binding
  • [H4] Drug-Drug Interactions
  • [H4] Biotransformation
  • [H4] Analytical Method Development & Bioanalysis
  • [H4] in vivo Pharmacokinetic & Pharmacodynamic Studies
  • [H4] PK & PK/PD Modelling and Simulation
  • [H4] DMPK Consultancy
  • [H4] Dedicated DMPK for Bifunctional Degraders: A Flexible Approach for Flexible Molecules
  • [H4] in vivo Pharmacology
  • [H4] CNS/Pain Models
  • [H4] Metabolic Disease Models
  • [H4] Inflammation & Immunology Models
  • [H4] Oncology Models
  • [H4] Non-Regulatory Toxicology
  • [H4] in vivo Pharmacokinetics
  • [H4] ex vivo Tissue Analysis
  • [H4] Evaluation of Two Novel Compounds Compared to Methadone on Morphine Withdrawal in a Rat Model of Physical dependence
  • [H4] Form & Formulation
  • [H4] Early Clinical Formulation
  • [H4] Solid Form Analysis
  • [H4] Salt and Co-Crystal Screening
  • [H4] Polymorph Screening
  • [H4] Pre-Clinical Formulation
  • [H4] Assessing Lypoprotectant Effect on Particle Size of Liposomal Systems
  • [H4] Modalities
  • [H4] Small Molecules
  • [H4] Peptides
  • [H4] Targeted protein degradation
  • [H4] ADCs
  • [H4] Biologics
  • [H4] Next-Generation Antibody Drug Conjugates
  • [H4] Ion Channels
  • [H4] GABAA Receptors
  • [H4] NMDA Receptors
  • [H4] Glycine Receptors
  • [H4] Nicotinic Receptors
  • [H4] TRP Channels
  • [H4] Sodium Channels
  • [H4] Calcium Channels
  • [H4] Potassium Channels
  • [H4] Chloride Channels
  • [H4] TMEM175
  • [H4] Delivering Custom Cell-Based Tools for Drug Discovery
  • [H4] Sygnature Discovery Successfully Provides Clinical Candidate to Corcept Therapeutics
  • [H4] Therapeutic Areas
  • [H4] Oncology and Immuno-Oncology
  • [H4] Inflammation and Immunology
  • [H4] Neuroscience
  • [H4] Metabolic Diseases
  • [H4] CellCentric Lead Optimisation Campaign - CCS1477
  • [H4] Blog
  • [H4] Webinars & Podcasts
  • [H4] Posters
  • [H4] Journal Papers
  • [H4] Technical Notes
  • [H4] Case Studies
  • [H4] eBooks
  • [H4] Protocols
  • [H4] News
  • [H4] Events
  • [H4] About Sygnature
  • [H4] Meet our Team
  • [H4] Careers
  • [H4] Integrated Drug Discovery
  • [H4] Target Identification & Validation
  • [H4] Hit Identification
  • [H4] Hit-to-Lead
  • [H4] Lead Optimization
  • [H4] STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
  • [H4] Modalities
  • [H4] Small Molecules
  • [H4] Peptides
  • [H4] Targeted protein degradation
  • [H4] ADCs
  • [H4] Biologics
  • [H4] Next-Generation Antibody Drug Conjugates
  • [H4] Therapeutic Areas
  • [H4] Oncology and Immuno-Oncology
  • [H4] Inflammation and Immunology
  • [H4] Neuroscience
  • [H4] Metabolic Diseases
  • [H4] CellCentric Lead Optimisation Campaign - CCS1477
  • [H4] About Sygnature
  • [H4] Meet our Team
  • [H4] Careers
  • [H4] UK (Nottingham)
  • [H5] Our Office Locations
  • [H5] Drug Discovery
  • [H5] modalities
  • [H5] Target Classes
  • [H5] Scientific solutions
  • [H5] Therapeutic Areas
  • [H5] Website
  • [H5] Resource Hub

Imagens

Encontrámos 77 imagens nesta página.

38 atributos ALT estão vazios ou em falta. É recomendado adicionar texto alternativo de modo a que os motores de busca identifiquem melhor o conteúdo das suas imagens.

Rácio Texto/HTML

Rácio : 26%

Ideal! O rácio de texto para código HTML desta página está entre 25 e 70 porcento.

Flash

Perfeito, não foi encontrado conteúdo Flash nesta página.

Iframe

Oh, não, esta página tem Iframes na página, o que significa que o conteúdo destas não pode ser indexado.

Reescrita de URL

Perfeito. As ligações aparentam ser limpas!

Underscores (traços inferiores) nas URLs

Detetámos 'underscores' (traços inferiores) nas suas URLs. O uso hífens é mais eficiente em termos de otimização SEO.

Ligações para a própria página

Encontrámos um total de 70 ligações incluindo 4 ligações a ficheiros

Âncoras Tipo Sumo
Explore the STORM Therapeutics case study Internas Passa sumo
Contact Internas Passa sumo
Contact us Internas Passa sumo
Get in touch Internas Passa sumo
What we do Internas Passa sumo
Learn more about Drug Discovery Internas Passa sumo
Learn more about Scientific Solutions Internas Passa sumo
Explore CADD Internas Passa sumo
Explore Protein and Structure Internas Passa sumo
Explore Bioscience Internas Passa sumo
Explore Chemistry Internas Passa sumo
Explore DMPK Internas Passa sumo
Explore in vivo Pharmacology Internas Passa sumo
Explore Form and Formulation Internas Passa sumo
Discover our Modalities Internas Passa sumo
Learn more about Target Classes Internas Passa sumo
Explore our Therapeutic Areas Internas Passa sumo
At Sygnature Discovery, we create exceptional scientific outcomes Internas Passa sumo
Reshaping drug discovery by uniting technology, disciplines and talent across Europe and North America Internas Passa sumo
Impact that lasts Internas Passa sumo
Learn more Internas Passa sumo
Read the case study Internas Passa sumo
Read the case study Internas Passa sumo
Read the case study Internas Passa sumo
Read the case study Internas Passa sumo
Read the case study Internas Passa sumo
Read the case study Internas Passa sumo
View our Careers Page Internas Passa sumo
Bringing Connected Drug Discovery Together Under One Name Internas Passa sumo
Dr Simon Hirst awarded prestigious honorary Doctorate from the University of Nottingham Internas Passa sumo
Sygnature Discovery Completes Major Enhancement of High-Throughput Chemistry Facilities Following £1 Million Investment Internas Passa sumo
Sygnature Discovery boosts growth of its in vivo Pharmacology business with appointment of new Vice President Internas Passa sumo
Sygnature Discovery Appoints New Chief Commercial Officer to Drive Next Phase of Business Growth Internas Passa sumo
Sygnature Discovery appoints Rick Davies to spearhead growth as Director of its UK Protein Sciences and Structural Biology business (formerly, Peak Proteins) Internas Passa sumo
View all locations Internas Passa sumo
Target Identification & Validation Internas Passa sumo
Hit Identification Internas Passa sumo
Hit-to-Lead Internas Passa sumo
Lead Optimization Internas Passa sumo
Small Molecules Internas Passa sumo
Peptides Internas Passa sumo
Targeted Protein Degradation Internas Passa sumo
ADCs Internas Passa sumo
Biologics Internas Passa sumo
Ion channels Internas Passa sumo
GPCRs Internas Passa sumo
Transporters Internas Passa sumo
Oncology Internas Passa sumo
Inflammation and Immunology Internas Passa sumo
Neuroscience Internas Passa sumo
Metabolic Diseases Internas Passa sumo
Meet our Team Internas Passa sumo
Working with us Internas Passa sumo
Environmental, social, governance Internas Passa sumo
Blog Internas Passa sumo
Webinars & Podcasts Internas Passa sumo
Posters Internas Passa sumo
Journal Papers Internas Passa sumo
Technical Notes Internas Passa sumo
eBooks Internas Passa sumo
Protocols Internas Passa sumo
Case Studies Internas Passa sumo
News Internas Passa sumo
Events Internas Passa sumo
Privacy Policy Internas Passa sumo
Cookie Policy Internas Passa sumo
Website terms of use Internas Passa sumo
Modern Slavery Statement Internas Passa sumo
Supplier Code of Conduct Internas Passa sumo
Website Design Agency Externas Passa sumo

Palavras-chave SEO

Núvem de palavras-chave

sygnature integrated discovery design target drug expertise chemistry solutions from

Consistência das Palavras-chave

Palavra-chave Conteúdo Título Palavras-chave Descrição Cabeçalhos
discovery 91
drug 68
sygnature 33
integrated 26
expertise 25

Usabilidade

Url

Domínio : sygnaturediscovery.com

Cumprimento : 22

Favicon

Ótimo, o site tem um favicon.

Facilidade de Impressão

Fantástico. Encontrámos CSS apropriado para impressão.

Língua

Otimo! A língua declarada deste site é en.

Dublin Core

Esta página não tira vantagens do Dublin Core.

Documento

Tipo de Documento

HTML 5

Codificação

Perfeito. O conjunto de caracteres UTF-8 está declarado.

Validação W3C

Erros : 0

Avisos : 0

Privacidade do Email

Aviso! No mínimo, foi encontrado um endereço de email sob a forma de texto. Isto é um convite para que spammers entupam a caixa de correio deste endereço.

HTML obsoleto

Fantástico! Não detetámos etiquetas HTML obsoletas.

Dicas de Velocidade

Excelente, este site não usa tablelas dentro de tabelas.
Oh não, o site usa estilos CSS nas etiquetas HTML.
Oh, não! O site utiliza demasiados ficheiros CSS (mais que 4).
Oh, não! O site utiliza demasiados ficheiros JavaScript (mais que 6).
Perfeito, o site tira vantagens da compressão gzip.

Dispositivos Móveis

Otimização para dispositivos móveis

Icon Apple
Meta Viewport Tag
Conteúdo Flash

Otimização

XML Sitemap

Perfeito, o site tem um mapa XML do site (sitemap).

https://www.sygnaturediscovery.com/sitemap_index.xml

Robots.txt

https://sygnaturediscovery.com/robots.txt

Perfeito, o seu site tem um ficheiro robots.txt.

Analytics

Em falta

Não detetámos nenhuma ferramenta analítica de análise de atividade.

Este tipo de ferramentas (como por exemplo o Google Analytics) permite perceber o comportamento dos visitantes e o tipo de atividade que fazem. No mínimo, uma ferramenta deve estar instalada, sendo que em algumas situações mais do que uma pode ser útil.

PageSpeed Insights

Dispositivo
Categorias

Free SEO Testing Tool

Free SEO Testing Tool é uma ferramenta gratuita que o ajuda a avaliar o seu site